Sabirnetug trial failure forces Acumen Pharmaceuticals to reassess Alzheimer’s drug development strategy
Acumen Pharmaceuticals halts sabirnetug after its Phase 2 Alzheimer's trial fails despite amyloid reduction. Discover what the findings mean.
Features & Analysis